CD34 and Hyperglycemia: Although we acknowledge that both the in vitro model of diabetes and the myeloid differentiation protocol of CD34+ HSPCs cannot fully recapitulate the environment of the diabetic BM and that the small number of cells obtained from sternal BM biopsies may limit the validation of the study, overall these data provide experimental evidence for hyperglycaemia/diabetes-induced reprogramming of haemopoiesis in human CD34+ HSPCs.